Loading…
Lipid-based nanoparticles for treatment of cancer
Investigators were continuously creating novel nanotechnologies to address unmet requirements throughout the administration of therapeutic medicines & imaging agents for cancer treatment & diagnostics, appropriately. LNPs(Lipid nanoparticles) are legitimate particulates (approx. 100 nm in si...
Saved in:
Published in: | Heliyon 2022-05, Vol.8 (5), p.e09403, Article e09403 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c533t-afae5a9b2a5d368c3e9ca50935c80b19d41e2399094d43f4d42a7ec9028f18383 |
---|---|
cites | cdi_FETCH-LOGICAL-c533t-afae5a9b2a5d368c3e9ca50935c80b19d41e2399094d43f4d42a7ec9028f18383 |
container_end_page | |
container_issue | 5 |
container_start_page | e09403 |
container_title | Heliyon |
container_volume | 8 |
creator | Sheoran, Sumit Arora, Swati Samsonraj, R. Govindaiah, Pilli vuree, Sugunakar |
description | Investigators were continuously creating novel nanotechnologies to address unmet requirements throughout the administration of therapeutic medicines & imaging agents for cancer treatment & diagnostics, appropriately. LNPs(Lipid nanoparticles) are legitimate particulates (approx. 100 nm in size) gathered from various lipid as well as other biochemical compounds which overall functionality to resolve biological barriers (biobarriers), allowing LNPs to selectively collect somewhere outside of disease-target cells again for responsive therapeutics. Most pharmaceutically important compounds were insoluble throughout water solutions, were chemical & physiologically unstable, or have toxicities. Among the most potential drug carrier for bioactive organic compounds is LBNPs (Lipid based nanoparticles) technologies. Its present use in chemotherapy have transformed treatment for cancer by increasing the antitumor effect of a number of chemotherapeutics. Because they may be created using naturally occurring sources, LBNPs have great temporal and thermal stability, maximum load potential, simplicity of preparations, cheap manufacturing costs, & big manufacturing output. Furthermore, combining chemotherapeutic drugs with LNPs reduces active therapeutic dosage and toxicities, lowers treatment resistance, & raises drug concentration in tumour cells while reducing concentrations in normal tissue. LBNPs were widely studied in cancer treatment, both in vitro and in vivo, with encouraging outcomes in certain clinical trials. This study provides an overview of the many types of LBNPs which have been created in latest years and their applications and contributions in different types of cancers.
Lipoid based nanoparticles; Tumour; Clinical trials; Liposomes; Solid lipid nanoparticles. |
doi_str_mv | 10.1016/j.heliyon.2022.e09403 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_3a25d775a3cd4a5b94c15d5aa5ea6a52</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2405844022006910</els_id><doaj_id>oai_doaj_org_article_3a25d775a3cd4a5b94c15d5aa5ea6a52</doaj_id><sourcerecordid>2674009174</sourcerecordid><originalsourceid>FETCH-LOGICAL-c533t-afae5a9b2a5d368c3e9ca50935c80b19d41e2399094d43f4d42a7ec9028f18383</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EolXpTwDlyCXL-DPxBYQqPiqtxAXO1sSetF5l48XOVuq_xyVL1Z642Jb9zjOv52XsLYcNB24-7Da3NMX7NG8ECLEhsArkC3YuFOi2VwpePjmfsctSdgDAdW9sJ1-zM6mNkZ2054xv4yGGdsBCoZlxTgfMS_QTlWZMuVky4bKneWnS2HicPeU37NWIU6HL037Bfn398vPqe7v98e366vO29VrKpcURSaMdBOogTe8lWY8arNS-h4HboDgJaW21HpQc6yKwI29B9CPvZS8v2PXKDQl37pDjHvO9Sxjd34uUb9zJqpModOg6jdIHhXqwynMdNKImNKhFZX1cWYfjsKfg64cyTs-gz1_meOtu0p2z3AAoUwHvT4Ccfh-pLG4fi6dpwpnSsThhOgVgeaeqVK9Sn1MpmcbHNhzcQ3pu507puYf03JperXv31ONj1b-squDTKqA69btI2RUfqUYSYia_1LHE_7T4A2c9rj4</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2674009174</pqid></control><display><type>article</type><title>Lipid-based nanoparticles for treatment of cancer</title><source>ScienceDirect Journals</source><source>PubMed Central</source><creator>Sheoran, Sumit ; Arora, Swati ; Samsonraj, R. ; Govindaiah, Pilli ; vuree, Sugunakar</creator><creatorcontrib>Sheoran, Sumit ; Arora, Swati ; Samsonraj, R. ; Govindaiah, Pilli ; vuree, Sugunakar</creatorcontrib><description>Investigators were continuously creating novel nanotechnologies to address unmet requirements throughout the administration of therapeutic medicines & imaging agents for cancer treatment & diagnostics, appropriately. LNPs(Lipid nanoparticles) are legitimate particulates (approx. 100 nm in size) gathered from various lipid as well as other biochemical compounds which overall functionality to resolve biological barriers (biobarriers), allowing LNPs to selectively collect somewhere outside of disease-target cells again for responsive therapeutics. Most pharmaceutically important compounds were insoluble throughout water solutions, were chemical & physiologically unstable, or have toxicities. Among the most potential drug carrier for bioactive organic compounds is LBNPs (Lipid based nanoparticles) technologies. Its present use in chemotherapy have transformed treatment for cancer by increasing the antitumor effect of a number of chemotherapeutics. Because they may be created using naturally occurring sources, LBNPs have great temporal and thermal stability, maximum load potential, simplicity of preparations, cheap manufacturing costs, & big manufacturing output. Furthermore, combining chemotherapeutic drugs with LNPs reduces active therapeutic dosage and toxicities, lowers treatment resistance, & raises drug concentration in tumour cells while reducing concentrations in normal tissue. LBNPs were widely studied in cancer treatment, both in vitro and in vivo, with encouraging outcomes in certain clinical trials. This study provides an overview of the many types of LBNPs which have been created in latest years and their applications and contributions in different types of cancers.
Lipoid based nanoparticles; Tumour; Clinical trials; Liposomes; Solid lipid nanoparticles.</description><identifier>ISSN: 2405-8440</identifier><identifier>EISSN: 2405-8440</identifier><identifier>DOI: 10.1016/j.heliyon.2022.e09403</identifier><identifier>PMID: 35663739</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Clinical trials ; Lipid based Nanopartcles ; Liposomes ; Review ; Solid lipid nanoparticles ; Tumour</subject><ispartof>Heliyon, 2022-05, Vol.8 (5), p.e09403, Article e09403</ispartof><rights>2022</rights><rights>2022 Published by Elsevier Ltd.</rights><rights>2022 Published by Elsevier Ltd. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c533t-afae5a9b2a5d368c3e9ca50935c80b19d41e2399094d43f4d42a7ec9028f18383</citedby><cites>FETCH-LOGICAL-c533t-afae5a9b2a5d368c3e9ca50935c80b19d41e2399094d43f4d42a7ec9028f18383</cites><orcidid>0000-0002-2519-8506 ; 0000-0002-3262-434X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160046/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2405844022006910$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3549,27924,27925,45780,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35663739$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sheoran, Sumit</creatorcontrib><creatorcontrib>Arora, Swati</creatorcontrib><creatorcontrib>Samsonraj, R.</creatorcontrib><creatorcontrib>Govindaiah, Pilli</creatorcontrib><creatorcontrib>vuree, Sugunakar</creatorcontrib><title>Lipid-based nanoparticles for treatment of cancer</title><title>Heliyon</title><addtitle>Heliyon</addtitle><description>Investigators were continuously creating novel nanotechnologies to address unmet requirements throughout the administration of therapeutic medicines & imaging agents for cancer treatment & diagnostics, appropriately. LNPs(Lipid nanoparticles) are legitimate particulates (approx. 100 nm in size) gathered from various lipid as well as other biochemical compounds which overall functionality to resolve biological barriers (biobarriers), allowing LNPs to selectively collect somewhere outside of disease-target cells again for responsive therapeutics. Most pharmaceutically important compounds were insoluble throughout water solutions, were chemical & physiologically unstable, or have toxicities. Among the most potential drug carrier for bioactive organic compounds is LBNPs (Lipid based nanoparticles) technologies. Its present use in chemotherapy have transformed treatment for cancer by increasing the antitumor effect of a number of chemotherapeutics. Because they may be created using naturally occurring sources, LBNPs have great temporal and thermal stability, maximum load potential, simplicity of preparations, cheap manufacturing costs, & big manufacturing output. Furthermore, combining chemotherapeutic drugs with LNPs reduces active therapeutic dosage and toxicities, lowers treatment resistance, & raises drug concentration in tumour cells while reducing concentrations in normal tissue. LBNPs were widely studied in cancer treatment, both in vitro and in vivo, with encouraging outcomes in certain clinical trials. This study provides an overview of the many types of LBNPs which have been created in latest years and their applications and contributions in different types of cancers.
Lipoid based nanoparticles; Tumour; Clinical trials; Liposomes; Solid lipid nanoparticles.</description><subject>Clinical trials</subject><subject>Lipid based Nanopartcles</subject><subject>Liposomes</subject><subject>Review</subject><subject>Solid lipid nanoparticles</subject><subject>Tumour</subject><issn>2405-8440</issn><issn>2405-8440</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqFkU1v1DAQhi0EolXpTwDlyCXL-DPxBYQqPiqtxAXO1sSetF5l48XOVuq_xyVL1Z642Jb9zjOv52XsLYcNB24-7Da3NMX7NG8ECLEhsArkC3YuFOi2VwpePjmfsctSdgDAdW9sJ1-zM6mNkZ2054xv4yGGdsBCoZlxTgfMS_QTlWZMuVky4bKneWnS2HicPeU37NWIU6HL037Bfn398vPqe7v98e366vO29VrKpcURSaMdBOogTe8lWY8arNS-h4HboDgJaW21HpQc6yKwI29B9CPvZS8v2PXKDQl37pDjHvO9Sxjd34uUb9zJqpModOg6jdIHhXqwynMdNKImNKhFZX1cWYfjsKfg64cyTs-gz1_meOtu0p2z3AAoUwHvT4Ccfh-pLG4fi6dpwpnSsThhOgVgeaeqVK9Sn1MpmcbHNhzcQ3pu507puYf03JperXv31ONj1b-squDTKqA69btI2RUfqUYSYia_1LHE_7T4A2c9rj4</recordid><startdate>20220501</startdate><enddate>20220501</enddate><creator>Sheoran, Sumit</creator><creator>Arora, Swati</creator><creator>Samsonraj, R.</creator><creator>Govindaiah, Pilli</creator><creator>vuree, Sugunakar</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-2519-8506</orcidid><orcidid>https://orcid.org/0000-0002-3262-434X</orcidid></search><sort><creationdate>20220501</creationdate><title>Lipid-based nanoparticles for treatment of cancer</title><author>Sheoran, Sumit ; Arora, Swati ; Samsonraj, R. ; Govindaiah, Pilli ; vuree, Sugunakar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c533t-afae5a9b2a5d368c3e9ca50935c80b19d41e2399094d43f4d42a7ec9028f18383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Clinical trials</topic><topic>Lipid based Nanopartcles</topic><topic>Liposomes</topic><topic>Review</topic><topic>Solid lipid nanoparticles</topic><topic>Tumour</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sheoran, Sumit</creatorcontrib><creatorcontrib>Arora, Swati</creatorcontrib><creatorcontrib>Samsonraj, R.</creatorcontrib><creatorcontrib>Govindaiah, Pilli</creatorcontrib><creatorcontrib>vuree, Sugunakar</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Heliyon</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sheoran, Sumit</au><au>Arora, Swati</au><au>Samsonraj, R.</au><au>Govindaiah, Pilli</au><au>vuree, Sugunakar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipid-based nanoparticles for treatment of cancer</atitle><jtitle>Heliyon</jtitle><addtitle>Heliyon</addtitle><date>2022-05-01</date><risdate>2022</risdate><volume>8</volume><issue>5</issue><spage>e09403</spage><pages>e09403-</pages><artnum>e09403</artnum><issn>2405-8440</issn><eissn>2405-8440</eissn><abstract>Investigators were continuously creating novel nanotechnologies to address unmet requirements throughout the administration of therapeutic medicines & imaging agents for cancer treatment & diagnostics, appropriately. LNPs(Lipid nanoparticles) are legitimate particulates (approx. 100 nm in size) gathered from various lipid as well as other biochemical compounds which overall functionality to resolve biological barriers (biobarriers), allowing LNPs to selectively collect somewhere outside of disease-target cells again for responsive therapeutics. Most pharmaceutically important compounds were insoluble throughout water solutions, were chemical & physiologically unstable, or have toxicities. Among the most potential drug carrier for bioactive organic compounds is LBNPs (Lipid based nanoparticles) technologies. Its present use in chemotherapy have transformed treatment for cancer by increasing the antitumor effect of a number of chemotherapeutics. Because they may be created using naturally occurring sources, LBNPs have great temporal and thermal stability, maximum load potential, simplicity of preparations, cheap manufacturing costs, & big manufacturing output. Furthermore, combining chemotherapeutic drugs with LNPs reduces active therapeutic dosage and toxicities, lowers treatment resistance, & raises drug concentration in tumour cells while reducing concentrations in normal tissue. LBNPs were widely studied in cancer treatment, both in vitro and in vivo, with encouraging outcomes in certain clinical trials. This study provides an overview of the many types of LBNPs which have been created in latest years and their applications and contributions in different types of cancers.
Lipoid based nanoparticles; Tumour; Clinical trials; Liposomes; Solid lipid nanoparticles.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>35663739</pmid><doi>10.1016/j.heliyon.2022.e09403</doi><orcidid>https://orcid.org/0000-0002-2519-8506</orcidid><orcidid>https://orcid.org/0000-0002-3262-434X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2405-8440 |
ispartof | Heliyon, 2022-05, Vol.8 (5), p.e09403, Article e09403 |
issn | 2405-8440 2405-8440 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_3a25d775a3cd4a5b94c15d5aa5ea6a52 |
source | ScienceDirect Journals; PubMed Central |
subjects | Clinical trials Lipid based Nanopartcles Liposomes Review Solid lipid nanoparticles Tumour |
title | Lipid-based nanoparticles for treatment of cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T08%3A26%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipid-based%20nanoparticles%20for%20treatment%20of%20cancer&rft.jtitle=Heliyon&rft.au=Sheoran,%20Sumit&rft.date=2022-05-01&rft.volume=8&rft.issue=5&rft.spage=e09403&rft.pages=e09403-&rft.artnum=e09403&rft.issn=2405-8440&rft.eissn=2405-8440&rft_id=info:doi/10.1016/j.heliyon.2022.e09403&rft_dat=%3Cproquest_doaj_%3E2674009174%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c533t-afae5a9b2a5d368c3e9ca50935c80b19d41e2399094d43f4d42a7ec9028f18383%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2674009174&rft_id=info:pmid/35663739&rfr_iscdi=true |